{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=CAB+LA+%2B+RPV+LA", "query": { "intervention": "CAB LA + RPV LA" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 24, "total_pages": 3, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=CAB+LA+%2B+RPV+LA&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-27T01:15:05.518Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03639311", "title": "Phase 2b, Open-label, Multicenter, Rollover Study to Assess Antiviral Activity and Safety of Long-acting (LA) Cabotegravir (CAB) Plus LA Rilpivirine (RPV), Administered Every 2 Months (Q2M), in Human Immunodeficiency Virus (HIV)-Positive Participants From the LATTE Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "CAB LA", "type": "DRUG" }, { "name": "RPV LA", "type": "DRUG" }, { "name": "RPV", "type": "DRUG" }, { "name": "DTG", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ViiV Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 97, "start_date": "2018-09-24", "completion_date": "2023-01-30", "has_results": true, "last_update_posted_date": "2024-06-11", "last_synced_at": "2026-09-27T01:15:05.518Z", "location_count": 25, "location_summary": "Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 20 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Bakersfield", "state": "California" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03639311" }, { "nct_id": "NCT06411223", "title": "Pharmacist-led Intervention for Injectable HIV Treatment for Women With Health-related Social Needs", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hiv" ], "interventions": [ { "name": "Collaborative drug therapy management model", "type": "BEHAVIORAL" }, { "name": "Cabotegravir/Rilpivirine", "type": "DRUG" } ], "intervention_types": [ "BEHAVIORAL", "DRUG" ], "sponsor": "Yale University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2024-08-01", "completion_date": "2027-03", "has_results": false, "last_update_posted_date": "2026-02-03", "last_synced_at": "2026-09-27T01:15:05.518Z", "location_count": 1, "location_summary": "New Haven, Connecticut", "locations": [ { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT06411223" }, { "nct_id": "NCT04973254", "title": "Improving Treatment and Retention Adherence in Nontraditional Settings", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "CAB-RPV LA", "type": "OTHER" }, { "name": "Standard treatment within an HIV clinic", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Boston Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2022-02-23", "completion_date": "2023-03-28", "has_results": true, "last_update_posted_date": "2025-01-15", "last_synced_at": "2026-09-27T01:15:05.518Z", "location_count": 2, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04973254" }, { "nct_id": "NCT02938520", "title": "Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Cabotegravir (CAB) tablet", "type": "DRUG" }, { "name": "Rilpivirine (RPV) tablet", "type": "DRUG" }, { "name": "Cabotegravir - Injectable Suspension (CAB LA)", "type": "DRUG" }, { "name": "Rilpivirine - Injectable Suspension (RPV LA)", "type": "DRUG" }, { "name": "ABC/DTG/3TC STR - Tablet", "type": "DRUG" }, { "name": "DTG Tablet", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ViiV Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 631, "start_date": "2016-10-27", "completion_date": "2029-12-31", "has_results": true, "last_update_posted_date": "2026-07-30", "last_synced_at": "2026-09-27T01:15:05.518Z", "location_count": 25, "location_summary": "Birmingham, Alabama • Bakersfield, California • Long Beach, California + 21 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Bakersfield", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02938520" }, { "nct_id": "NCT04001803", "title": "Study to Identify and Determine Best Implementation Practices for Injectable Cabotegravir+Rilpivirine in the United States (US)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "CAB LA+RPV LA", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ViiV Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 115, "start_date": "2019-07-08", "completion_date": "2022-03-18", "has_results": true, "last_update_posted_date": "2023-04-14", "last_synced_at": "2026-09-27T01:15:05.518Z", "location_count": 9, "location_summary": "Sacramento, California • Washington D.C., District of Columbia • Jacksonville, Florida + 6 more", "locations": [ { "city": "Sacramento", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Miami Beach", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04001803" }, { "nct_id": "NCT06451341", "title": "IMplementation of CAB+RPV LA for People With HIV in Non-Metropolitan Areas", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "HIV" ], "interventions": [ { "name": "Acceptability of Intervention Measure (AIM)", "type": "BEHAVIORAL" }, { "name": "Intervention Appropriateness Measure (IAM)", "type": "BEHAVIORAL" }, { "name": "Feasibility of Intervention Measure (FIM)", "type": "BEHAVIORAL" }, { "name": "HIV Stigma Scale Questionnaire", "type": "BEHAVIORAL" }, { "name": "HIV Treatment Satisfaction Questionnaire status version (HIVTSQs12)", "type": "BEHAVIORAL" }, { "name": "HIV Treatment Satisfaction Questionnaire change version (HIVTSQc12)", "type": "BEHAVIORAL" }, { "name": "Needs and Barriers Assessment", "type": "BEHAVIORAL" }, { "name": "Pre-visit Outreach", "type": "BEHAVIORAL" }, { "name": "Qualitative interview - patient participants", "type": "BEHAVIORAL" }, { "name": "Staff education", "type": "BEHAVIORAL" }, { "name": "Staff Month 7 and 15 Survey - Staff Burden and Engagement", "type": "BEHAVIORAL" }, { "name": "Qualitative interview - staff", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "University of Nebraska", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": null, "sex": "ALL", "summary": "19 Years and older" }, "enrollment_count": 75, "start_date": "2024-07-01", "completion_date": "2028-05", "has_results": false, "last_update_posted_date": "2026-07-24", "last_synced_at": "2026-09-27T01:15:05.518Z", "location_count": 4, "location_summary": "Harlan, Iowa • Shenandoah, Iowa • Grand Island, Nebraska + 1 more", "locations": [ { "city": "Harlan", "state": "Iowa" }, { "city": "Shenandoah", "state": "Iowa" }, { "city": "Grand Island", "state": "Nebraska" }, { "city": "Omaha", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT06451341" }, { "nct_id": "NCT05660980", "title": "Study of Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in Virologically Suppressed Children Living With HIV-1, Two to Less Than 12 Years of Age", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "HIV-1-infection" ], "interventions": [ { "name": "Once daily CAB tablet + RPV tablet", "type": "DRUG" }, { "name": "Long acting CAB injectable + long acting RPV injectable", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "11 Years", "sex": "ALL", "summary": "2 Years to 11 Years" }, "enrollment_count": 90, "start_date": "2024-01-24", "completion_date": "2029-03-31", "has_results": false, "last_update_posted_date": "2026-05-19", "last_synced_at": "2026-09-27T01:15:05.518Z", "location_count": 2, "location_summary": "Atlanta, Georgia • Memphis, Tennessee", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Memphis", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT05660980" }, { "nct_id": "NCT03299049", "title": "Efficacy, Safety and Tolerability Study of Long-acting Cabotegravir Plus Long-acting Rilpivirine (CAB LA + RPV LA) in Human-immunodeficiency Virus-1 (HIV-1) Infected Adults", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Cabotegravir Tablets", "type": "DRUG" }, { "name": "Rilpivirine Tablets", "type": "DRUG" }, { "name": "Cabotegravir Injectable Suspension", "type": "DRUG" }, { "name": "Rilpivirine Injectable Suspension", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ViiV Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1049, "start_date": "2017-10-27", "completion_date": "2029-12-31", "has_results": true, "last_update_posted_date": "2025-08-22", "last_synced_at": "2026-09-27T01:15:05.518Z", "location_count": 43, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Bakersfield, California + 33 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Bakersfield", "state": "California" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Long Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03299049" }, { "nct_id": "NCT03635788", "title": "The LATITUDE Study: Long-Acting Therapy to Improve Treatment SUccess in Daily LifE", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Standard of Care (SOC) Oral ART", "type": "DRUG" }, { "name": "Oral RPV", "type": "DRUG" }, { "name": "Oral CAB", "type": "DRUG" }, { "name": "RPV-LA Loading Dose", "type": "DRUG" }, { "name": "CAB-LA Loading Dose", "type": "DRUG" }, { "name": "RPV-LA Maintenance Dose", "type": "DRUG" }, { "name": "CAB-LA Maintenance Dose", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 456, "start_date": "2019-03-28", "completion_date": "2026-08-17", "has_results": true, "last_update_posted_date": "2026-09-17", "last_synced_at": "2026-09-27T01:15:05.518Z", "location_count": 32, "location_summary": "Birmingham, Alabama • Los Angeles, California • San Diego, California + 24 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03635788" }, { "nct_id": "NCT05917509", "title": "A Study to Evaluate the Efficacy, Safety, Participant Choice and Preference of an Oral Once-daily Regimen or a Long-acting Injectable Regimen Every Two Months for Treatment of Human Immunodeficiency Virus (HIV-1) in Adults Who Have Not Previously Taken Antiretroviral Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "DTG/3TC", "type": "DRUG" }, { "name": "Cabotegravir (CAB) LA", "type": "DRUG" }, { "name": "Rilpivirine (RPV) LA", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ViiV Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 171, "start_date": "2023-07-06", "completion_date": "2026-04-20", "has_results": false, "last_update_posted_date": "2026-05-27", "last_synced_at": "2026-09-27T01:15:05.518Z", "location_count": 15, "location_summary": "Birmingham, Alabama • Bakersfield, California • Fort Lauderdale, Florida + 12 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Bakersfield", "state": "California" }, { "city": "Fort Lauderdale", "state": "Florida" }, { "city": "Ft. Pierce", "state": "Florida" }, { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05917509" } ] }